1. A pharmaceutical composition for treating or preventing cardiovascular disease, wherein the pharmaceutical composition contains at least about 90% EPA by weight of all fatty acids present in the composition and a cardiovascular agent. The composition of claim 1, wherein the cardiovascular agent is an ACAT inhibitor, an ACE inhibitor, an alpha blocker, an alpha / beta blocker, an angiotensin II receptor antagonist, an antiarrhythmic agent, an antiplatelet agent, a beta blocker, a calcium channel blocker, a reductase inhibitor HMG-CoA, apoA-1 mimetic, CETP inhibitor, bile acid excretion enhancer, cholesterol absorption inhibitor, diuretic, anti-dyslipidemia agent, endothelin receptor antagonist, LDL receptor inducer, Lp-PLA2 inhibitor, squalene epoxidase inhibitor, ac ivator LCAT, an inhibitor of microsomal triglyceride transfer protein inhibitor, sPLA2, 5-lipoxygenase inhibitor, an agonist / activator of PPAR, thrombolytic agent, an activator thyroid beta receptor, a platelet aggregation inhibitor or antagonist aldosterona.3. The composition of claim 1, wherein the cardiovascular agent is selected from the group consisting of 5-LO 6, A-0002, abciximab, ABT-335, ABT-761, acebutolol, adenosine, AEGR-733, aldactone, aliskiren, aliskiren hemifumarate , alliin, amiodarone, amlodipine, anacetrapib, APA-01, apixaban, APL180, APP018, aspirin, atenolol, atorvastatin, AVE5530, AZD-2479, BAY-60-5521, benazepril, BMS-200150, bosentan, capanopartan, butenefen, , carvedilol, CER-002, sodium chlortiazide, chlorpropamide, cholinophenofibrate, CI-1011, cilostazol, clevidipine butyrate, clonidine, clopidogrel, CMI 977, wheel lover, colestipol, CP-346086, CP-8005656 9, CRD-5, CS-1. Фармацевтическая композиция для лечения или профилактики сердечно-сосудистых заболеваний, где фармацевтическая композиция содержит по меньшей мере приблизительно 90% EPA по массе от всех жирных кислот, присутствующих в композиции и сердечно-сосудистое средство.2. Композиция по п. 1, где сердечно-сосудисто
